The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC).
 
Rana R. McKay
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Dylan Martini
No Relationships to Disclose
 
Raphael Brandao Moreira
No Relationships to Disclose
 
Lana Hamieh
No Relationships to Disclose
 
Craig Norton
No Relationships to Disclose
 
Stephanie Anne Mullane
No Relationships to Disclose
 
Meghara K. Walsh
No Relationships to Disclose
 
Dror Michaelson
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Eliezer VanAllen
Stock and Other Ownership Interests - Synapse
Consulting or Advisory Role - Genome Medical (Inst); Third Rock Ventures (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Lauren Christine Harshman
Consulting or Advisory Role - Dendreon; Genentech; KEW; Medivation/Astellas; NCCN; Pfizer; PlatformQ Health; Theragene
Research Funding - Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Medivation/Astellas (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)